Mutual of America Capital Management LLC cut its stake in Omeros Corporation (NASDAQ:OMER) by 3.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 108,376 shares of the biopharmaceutical company’s stock after selling 3,756 shares during the period. Mutual of America Capital Management LLC owned about 0.25% of Omeros Corporation worth $2,157,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Bank of New York Mellon Corp increased its stake in Omeros Corporation by 2.8% in the 1st quarter. Bank of New York Mellon Corp now owns 225,583 shares of the biopharmaceutical company’s stock worth $3,411,000 after buying an additional 6,043 shares during the period. Wells Fargo & Company MN lifted its holdings in Omeros Corporation by 5.5% during the 1st quarter. Wells Fargo & Company MN now owns 37,717 shares of the biopharmaceutical company’s stock valued at $571,000 after buying an additional 1,960 shares in the last quarter. UBS Group AG lifted its holdings in Omeros Corporation by 4.2% during the 1st quarter. UBS Group AG now owns 398,356 shares of the biopharmaceutical company’s stock valued at $6,023,000 after buying an additional 16,075 shares in the last quarter. Swiss National Bank lifted its holdings in Omeros Corporation by 5.7% during the 1st quarter. Swiss National Bank now owns 67,100 shares of the biopharmaceutical company’s stock valued at $1,015,000 after buying an additional 3,600 shares in the last quarter. Finally, Teachers Advisors LLC lifted its holdings in Omeros Corporation by 9.2% during the 4th quarter. Teachers Advisors LLC now owns 63,334 shares of the biopharmaceutical company’s stock valued at $628,000 after buying an additional 5,347 shares in the last quarter. Hedge funds and other institutional investors own 44.93% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://www.thecerbatgem.com/2017/10/03/omeros-corporation-omer-shares-sold-by-mutual-of-america-capital-management-llc.html.

Several equities research analysts have issued reports on OMER shares. Zacks Investment Research cut shares of Omeros Corporation from a “hold” rating to a “sell” rating in a research report on Friday, June 23rd. BidaskClub raised shares of Omeros Corporation from a “hold” rating to a “buy” rating in a research report on Sunday, June 18th. Wedbush reaffirmed an “outperform” rating and set a $47.00 target price on shares of Omeros Corporation in a research report on Friday, August 18th. Maxim Group reaffirmed a “buy” rating and set a $24.00 price target (up previously from $23.00) on shares of Omeros Corporation in a research note on Tuesday, August 8th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $19.00 price target (up previously from $15.00) on shares of Omeros Corporation in a research note on Thursday, August 24th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Omeros Corporation has a consensus rating of “Buy” and an average price target of $33.38.

Omeros Corporation (NASDAQ:OMER) opened at 22.34 on Tuesday. The firm’s 50-day moving average is $21.09 and its 200-day moving average is $18.81. Omeros Corporation has a 52-week low of $7.20 and a 52-week high of $27.09. The stock’s market cap is $1.00 billion.

Omeros Corporation (NASDAQ:OMER) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.12. The firm had revenue of $17.15 million for the quarter, compared to analysts’ expectations of $14.63 million. During the same quarter last year, the business earned ($0.32) earnings per share. The business’s revenue was up 71.5% compared to the same quarter last year. Equities research analysts predict that Omeros Corporation will post ($1.30) earnings per share for the current year.

Omeros Corporation Profile

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Corporation (NASDAQ:OMER).

Institutional Ownership by Quarter for Omeros Corporation (NASDAQ:OMER)

Receive News & Stock Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related stocks with our FREE daily email newsletter.